**FISH For ALK**

**Background Information**

The Food and Drug Administration's August 2011 approval of the targeted therapy crizotinib (Xalkori®, Pfizer, New York, N.Y.) and the companion diagnostic assay Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular, Inc., Chicago, Ill.) opened the door to a new era in the treatment of late-stage non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer death in men and women worldwide. Approximately 85% of all lung cancers are of non-small cell type. Advances in surgical treatment and combination therapies have marginally improved the average one-year survival rate (38% for stage IA-IIIB, Source: National Cancer Institute Surveillance, Epidemiology, and End Results [SEER] database) from the period 1975-1979 to the present; the five-year survival rate for all stages of lung cancer combined remains at 15%. The primary reason is that nearly 85% of cases present at an advanced stage.

Crizotinib is highly effective in treating patients whose NSCLC tumors harbor a rearrangement of the anaplastic lymphoma kinase (ALK) gene. The ALK-FISH assay allows for selection of the subgroup of NSCLC patients who are potentially therapy responsive based on identification of ALK rearrangements at the 2p23 chromosome in the tumor genome. This genetic alteration occurs in 2 to 7% of NSCLC patients.

The ALK gene encodes for a transmembrane glycoprotein with tyrosine kinase activity that normally is expressed only in select neuronal cell types. The constitutive kinase activity of ALK is essential for cellular proliferation in this subset of NSCLC. Gene rearrangements in the presence of known fusion partners, including EML4, TFG and KIF5B, result in a chimeric protein with tyrosine kinase activity. In particular the EML4/ALK fusion appears to be a key driver of tumorigenesis in NSCLC. The EML4/ALK fusion also has been identified in about 2.5% of breast and colon carcinomas using exonic sequencing.

**Methodology**

ALK rearrangements are typically mutually exclusive from EGFR and KRAS mutations, and the majority are found in adenocarcinomas. Patients with tumors exhibiting ALK rearrangements are usually younger, male and light or never-smokers. Lung adenocarcinomas with ALK rearrangement occur in 15% of this population with advanced stage NCSLC.

Crizotinib works by blocking certain kinases, including those produced by the abnormal ALK gene. Studies demonstrate crizotinib treatment of patients with tumors exhibiting ALK rearrangements can halt tumor progression or result in tumor regression.

**ALK rearrangements are typically mutually exclusive from EGFR and KRAS mutations, and the majority are found in adenocarcinomas. Patients with tumors exhibiting ALK rearrangements are usually younger, male and light or never-smokers. Lung adenocarcinomas with ALK rearrangement occur in 15% of this population with advanced stage NCSLC.**

Crizotinib works by blocking certain kinases, including those produced by the abnormal ALK gene. Studies demonstrate crizotinib treatment of patients with tumors exhibiting ALK rearrangements can halt tumor progression or result in tumor regression.

**Methodology**

**ALK FISH** is a qualitative fluorescence in situ hybridization (FISH) test that detects ALK gene rearrangements with all potential fusion partners, including EML4, TFG and KIF5B. It is the only diagnostic assay approved by the FDA for in vitro diagnostic (IVD) use to predict response to crizotinib. Other available molecular testing methodologies such as RT-PCR detect only the fusion target for which they have been constructed (e.g. EML4/ALK fusion product) and, of course, other potentially clinically significant fusion targets will not be detected.

The Abbott Molecular Vysis (AMV) ALK FISH kit was used in one of the two single-arm trials leading to the FDA-approval of crizotinib and has become the gold standard for detecting ALK rearrangement in NSCLC. The AMV ALK Break Apart FISH Probe mixture consists of two fluorophore-labeled DNA probes in hybridization buffer containing dextran sulfate, formamide, and SSC with blocking DNA. The two probes used are Vysis LSI 3′-ALK SpectrumOrange and LSI 5′-ALK SpectrumGreen.
The FDA-approved version of the test is performed on a formalin-fixed paraffin-embedded NSCLC tissue specimen. Alternative approaches using cytopathology ThinPrep slides for probe hybridization with morphologic correlation are under active development. Following appropriate specimen preparation, the specimen is hybridized using the probe mixture described above at 37°C for 14 to 24 hours. After washing and counterstaining, slides are evaluated for adequate hybridization. Slides are then assessed for the quality of the ALK signal and the tissue morphology. Signals from 50 tumor cells from representative areas of the slide are recorded. Depending on the monoclonal antibody and concentration used in IHC, overall sensitivity of IHC for ALK rearrangements ranges from 80 to 95% with specificity of 100%. A testing algorithm using IHC as an initial screening in all cases of NSCLC has been proposed in which ALK IHC 2+ tumor cells would undergo ALK-FISH; 3+ cells would be reported as ALK-positive; 0 and 1+ cells would be reported as ALK-negative. However, no IHC assay for ALK rearrangements has been cleared by the FDA for IVD, and its use remains investigational.

**Clinical Indications**

Patients with late-stage, non-small cell lung cancers may benefit from treatment with crizotinib. The National Comprehensive Cancer Network (NCCN Guidelines™) recognizes FISH as a specifically designed method for diagnosing ALK-rearranged adenocarcinomas. These guidelines recommend ALK testing concurrent with EGFR mutation testing in the diagnosis of adenocarcinoma, large cell and other nonspecified histologic subsets of NSCLC. Investigation into the role of IHC staining with monoclonal antibodies specific for ALK protein in identifying patients with ALK rearrangements continues. IHC can be performed on small biopsies, may be less sensitive to variations in fixation conditions than FISH and can be performed in routine daily practice.

**Interpretation**

When hybridized with the ALK FISH probes, the 2p23 ALK region in its native state will be observed as two immediately adjacent or fused (overlapping) orange/green (yellow) signals. However, if a chromosome rearrangement at the 2p23 ALK breakpoint region has occurred, one orange and one green signal separated by at least two signal diameters will be identified. Alternatively, a single orange signal (deletion of green signal) in addition to a fused or broken apart signal may be observed.

Cells are considered negative (non-rearranged) when orange and green signals are adjacent or fused (appear yellow under the Orange/Green V2 filter). A single green signal without a corresponding orange signal is also abnormal, but represents a rearrangement at the 2p23 locus that is not predictive of over-expressed ALK protein. Orange and green signals that are less than two signal diameters apart are classified as a single fused signal.

Cells are considered positive for a rearrangement when at least one set of orange and green signals are two or more signal diameters apart, or a single orange signal occurs without a corresponding green signal in addition to fused and/or broken apart signals. Multiple 2p23 signals are often observed as well, indicative of either genomic gain at 2p23 or an aneusomic state for chromosome 2.
A sample is considered negative if < 5 cells out of 50 (< 5/50 or < 10%) are positive. A sample is considered positive if > 25 cells out of 50 (> 25/50 or > 50%) are positive. A sample is considered equivocal if 5 to 25 cells (10 - 50%) are positive. If the sample is equivocal, a second technologist is required to evaluate the slide. The first and second cell count readings are added together, and a percent is calculated of 100 cells, the average percent of positive cells. If the average percent positive cells is < 15% (< 15/100), the sample is considered negative. If the average percent positive cells is ≥ 15% (≥ 15/100), the sample is considered positive.

**ALK FISH** demonstrates consistency of results across all readers with an overall percent agreement of 97.64 (95% CI: 96.25, 98.52). The positive percent agreement is 96.46 (95% CI: 94.40, 97.78), and the negative percent agreement is 100.00 (95% CI: 98.42, 100.00).

Patients who are **ALK**-positive are candidates for crizotinib therapy. For patients who are responsive to treatment, crizotinib yields significant clinical benefits. However, not all **ALK**-positive patients will respond, and those who do will eventually develop resistance to crizotinib. Time-to-drug resistance is unknown as yet; a variety of underlying molecular mechanisms are responsible for development of resistance.

**Limitations of the Assay**

This FISH assay is intended to be used for therapeutic purposes in lung cancer. It does not rule out other chromosome abnormalities. Results may indicate likely response to **ALK** inhibitor therapy, however, selection of treatment remains a clinical decision.

**References**

**Test Overview**

<table>
<thead>
<tr>
<th>Test Name</th>
<th>FISH for ALK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordering Mnemonic</td>
<td>ALKFISH</td>
</tr>
<tr>
<td>Methodology</td>
<td>Qualitative fluorescence <em>in situ</em> hybridization (FISH)</td>
</tr>
<tr>
<td>Specimen Requirements</td>
<td>Formalin-fixed, paraffin-embedded, primary or metastatic non-small cell lung carcinoma tissue in specimen blocks OR unstained specimen slides of paraffin sections 5 +/- 1µm thick on electrostatically charged (&quot;plus&quot;) slides</td>
</tr>
<tr>
<td>Clinical Information</td>
<td>The presence of an ALK rearrangement detected by FISH may qualify the patient for treatment with crizotinib.</td>
</tr>
<tr>
<td>Reference Range</td>
<td>ALK Negative: &lt; 5 cells out of 50 (&lt; 10%) are positive; ALK Positive: &gt; 25 cells out of 50 (&gt; 50%) are positive; ALK Equivocal: 5 to 25 cells (10-50%) are positive. <strong>Note: If the sample is equivocal, a second technologist is required to evaluate the slide.</strong></td>
</tr>
<tr>
<td>Billing Code</td>
<td>84330</td>
</tr>
<tr>
<td>CPT Code</td>
<td>88368 x 2</td>
</tr>
</tbody>
</table>

**Technical Information Contact:**
Wendy Nedlik, MT(ASCP)
216.444.8410
nedlikw@ccf.org

**Scientific Information Contact:**
Roger Klein, MD, JD
216.445.0776
kleinr3@ccf.org